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ABSTRACT 
In influenza vaccination studies assessing vaccine effectiveness (VE), both specific and non-specific endpoints (outcomes) 
are used. We present a formula for the relationship between VE against influenza-related outcomes (VEE), specific 
and non-specific, and that against influenza infection (VEI). In its simplest form, the formula comprises two additional 
parameters: the influenza attack rate among unvaccinated subjects, and the relative risk of the outcome for influenza 
infected subjects versus non-infected subjects. Both parameters may show large between-seasonal variation, which 
translates to a large between-seasonal variation of VEE estimates. With the full form of the formula it can be shown that, 
contrary to popular believe, VEE may be greater than VEI. We argue that interpreting VEE estimates in terms of “low” or 
“high” is not possible without taking the costs of an outcome case into account. We conclude that the decision to use a 
non-specific endpoint as surrogate for influenza infection should be taken in the awareness of these limitations.
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INTRODUCTION
Influenza vaccine effectiveness field studies are 
conducted to assess vaccine effectiveness, i.e. to assess 
how well vaccinated subjects are protected against 
influenza infection in the “real world”. In such studies, 
both specific and non-specific endpoints are employed. 
A specific endpoint is based on a laboratory test for 
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influenza infection, e.g. the real-time polymerase chain 
reaction (PCR) test [1]. A non-specific endpoint refers to 
an influenza-related but not laboratory-confirmed clinical 
syndrome. An example of such a syndrome is e.g. 
influenza-like illness (ILI), a respiratory illness characterized 
by fever, fatigue, cough and other symptoms. Influenza is 
not the only cause of ILI, it can be caused by other viruses 
as well, for example by the norovirus (the “winter vomiting 
bug”), the most common cause of viral gastroenteritis. 
Because influenza is not the only cause of ILI, the syndrome 
is non-specific for influenza. One reason for using non-
specific endpoints as surrogate for infection in influenza 
vaccine effectiveness studies is ease of case finding, as 
usually non-specific endpoint cases are easier to identify 
than specific endpoint cases (see below.)  
It is well-known that both specific and non-specific 
endpoints may lead to a biased estimate of the underlying 
vaccine effectiveness against influenza infection, denoted 
here by VEI. Vaccine effectiveness is defined as the fraction 
of influenza cases directly prevented by the vaccination. It 
can be any value between zero (no cases prevented) and 
one (100% of cases prevented). A non-specific endpoint 
as surrogate for influenza infection will, as is generally 
assumed, underestimate VEI. The reason for this is that there 
may be endpoint cases due to other causes than influenza 
infection, cases that cannot be prevented by influenza 
vaccination [2]. Assume, for example, that the vaccine 
effectiveness against influenza is 0.75, but that one-fifth 
of the endpoint cases is due to other causes. Influenza 
vaccination will prevent 75% of the endpoint cases caused 
by influenza, but only 0.75 x 0.8 = 60% of all endpoint 
cases. However, using a specific endpoint as surrogate for 
influenza infection also may not yield fully accurate results. 
A laboratory test for influenza infection will usually only 
be done in case of clinical signs and symptoms, which 
means that non-symptomatic influenza infections will go 
undetected. Also, when the PCR test is used to determine 
infection, a nasopharyngeal swab must be collected. It may 
not be possible to collect all specimens within a few days 
of symptoms onset and the laboratory test may be done too 
late, after viral shedding has stopped, causing a number of 
influenza cases to be missed and VEI to be underestimated. 
This is why specific endpoint are generally more difficult to 
identify than non-specific ones. Conversely, if less severe 
influenza cases go undetected by the laboratory test, and 
the less severe cases are predominantly in the vaccinated 
group, overestimation of VEI may occur, as has been 
pointed out by Nauta [3]. 
To improve understanding of the relationship between 
vaccine effectiveness against influenza infection and that 
against specific and non-specific endpoints, we felt a 
formula would be helpful. From the formula it follows that, 
contrary to popular believe, vaccine effectiveness against 
a non-specific endpoint can be greater than vaccine 
effectiveness against influenza infection. The added 
Public Health value of the formula is twofold. First, it may 
help investigators to better understand the limitations of 
non-specific endpoints. Second, it may help health care 
workers to correctly interpret estimates of influenza vaccine 
effectiveness against serious clinical endpoints such as 
pneumonia or pulmonary embolism. We will show that 
these estimates can vary considerably between seasons 
and require a different interpretation than estimates of 
influenza vaccine effectiveness against infection.
METHODS
Formula for the relationship between vaccine 
effectiveness against influenza-related endpoints and 
vaccine effectiveness against influenza infection
Influenza infection may be defined as the biological 
process of viral intrusion of upper respiratory cells and 
replication of new influenza virus particles. The standard 
measure for vaccine effectiveness against influenza 
infection is one minus the relative risk of influenza infection 
for vaccinated versus unvaccinated subjects:
VEI = 1–Rv(I)/Ru(I)  (1)
where Rv(I) and Ru(I) are the respective risks of influenza 
infection for vaccinated and unvaccinated subjects during 
the influenza season [4]. These risks are usually called 
“influenza attack rates” [5]. VEI is the fraction of influenza 
cases directly prevented by the vaccination and not by 
other, indirect, vaccine effects such as herd immunity [6]. 
VEI can take on any value between zero (no influenza 
cases prevented, Rv(I) = Ru(I)) and one (all influenza cases 
prevented, Rv(I) = 0.)
Likewise, the standard measure for vaccine 
effectiveness against an influenza-related endpoint is
VEE = 1–Rv(E)/Ru(E)  (2)
where Rv(E) is the risk of the endpoint for vaccinated 
subjects during the influenza season, and Ru(E) that for 
unvaccinated subjects. VEE is the fraction of prevented 
endpoint cases. The maximum value for VEE will be lower 
than one because there are endpoint cases that are not 
caused by influenza and which thus cannot be prevented 
by influenza vaccination.
The derivation of the formula for the relationship 
between VEE and VEI can be followed in the Appendix. 
In its simplest form, the formula comprises two parameters: 
Ru(I) (see equation 1), the risk of influenza infection for 
unvaccinated subjects, and RR(E), the relative risk of the 
endpoint for influenza infected subjects versus non-infected 
subjects:
         (3) 
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RR(E) is a measure of the strength of the relationship 
between the endpoint and influenza infection. It is strong 
for specific endpoints, weaker for non-specific endpoints, 
and one in case there is no relationship at all between 
the endpoint and influenza infection (like for the endpoint 
toothache for example).
Example 1. Consider the use of ILI as surrogate 
endpoint for symptomatic influenza infection. Because 
by definition all symptomatic influenza cases develop ILI 
symptoms, the risk of ILI for influenza infected subjects is 
1.0. Jackson et al. [7] find that the risk of ILI for subjects 
who do not get influenza infected is approximately 0.097. 
Thus, RR(ILI) ≈ 1.0/0.097 = 10.3, a value implying that 
the strength of the relationship between ILI and symptomatic 
influenza infection is only modest. Now, if VEI = 0.70 and 
the influenza attack rate between seasons varies between 
0.01 and 0.10, then, according to formula (3), VEE will 
vary between 0.060 and 0.337, due to this variation 
in the attack rate. This is a rather wide range and what 
is more, it shows that with a non-specific surrogate 
endpoint such as ILI, VEI (here 0.70) can be considerably 
underestimated.
From (3) it follows that 
     (4)
Thus, VEE is always smaller than 1.0. This has 
considerable consequences for the interpretation of VEE.
Example 2. In influenza VE studies, non-specific 
endpoints are sometimes employed not as surrogate for 
influenza infection, but because the endpoint is serious 
or life-threatening and an investigator wishes to assess 
the impact of influenza vaccination on its incidence. An 
example of a serious endpoint would be myocarditis 
(inflammation of the heart muscle), most often caused by a 
viral infection. Jackson et al. find RR(Myocarditis) = 2.1 [7]. 
Given that the attack rate of (seasonal) influenza will rarely 
be larger than 0.15, the vaccine effectiveness against 
myocarditis will be at most (2.1-1.0)/(2.1-1.0+1/0.15) 
= 0.14 (14% of myocarditis cases prevented). 
Formula (3) rests on two assumptions, namely i.) that 
the endpoint risk does not differ between vaccinated and 
unvaccinated non-infected subjects, and ii.) that it does 
not differ between vaccinated and unvaccinated infected 
subjects. Because vaccination state is not likely to influence 
the risk of developing the endpoint due to other pathogens 
than influenza virus, the first assumption will usually be 
met. The second assumption, however, will not be met if 
vaccinated infected subjects become less clinically ill from 
the infection, making them less susceptible to the endpoint 
compared to unvaccinated infected subjects. We use the 
symbol γ to express this difference in susceptibility. The full 
formula for the relationship between VEE and VEI then is
   (5)
If, for example, γ = 0.8, the risk of the endpoint 
for vaccinated infected subjects is 0.8 times the risk for 
unvaccinated infected subjects. RRu(E) is the relative risk of 
the endpoint for influenza infected unvaccinated subjects 
versus non-infected unvaccinated subjects. 
Example 3. Assume that VEI = 0.7, RRu(E) = 9.0, Ru(I) 
= 0.05 and γ = 1.0. Then VEE = 0.2 (20% of endpoint 
cases prevented by influenza vaccination). Next, assume 
that γ = 0.6. Then VEE = 0.24 (24% of cases prevented). 
This is explained by the fact that vaccinated endpoint 
cases are not only prevented by the vaccination but also 
by being less susceptible to the endpoint when infected.
Interestingly, formula (5) indicates that, contrary to 
popular believe, VEE can be larger than VEI. As a rule of 
the thumb, this will be the case when γ is not close to 1.0 
or when RRu(E) is large. For example when γ = 0.6, RRu(E) 
= 100, Ru(I)= 0.11 and VEI = 0.70, then VEE = 0.75 > VEI
DISCUSSION
We hope that our formula will help investigators and 
health care workers to better understand influenza vaccine 
effectiveness against other endpoints than influenza 
infection.
The measure to capture influenza vaccine effectiveness 
against infection, VEI, is not a constant of nature. Instead, 
it shows seasonal variation as it depends, amongst others, 
on the antigenic match between vaccine component and 
circulating strain, and pre-seasonal immunity (including 
the effects of previous vaccinations). This may modulate 
antibody response. The use of particular non-specific 
endpoints as surrogate for influenza infection will add to 
this variation, and, as we saw, the additional variation 
can be considerable. The most important reason for 
this additional variation is the between-season variation 
in influenza attack rate. There are seasons with wide 
epidemic spread, affecting large parts of the population, 
and non-epidemic seasons with sporadic outbreaks only. 
The attack rate itself is a combined parameter consisting 
of the epidemic strength (risk of exposure) and the natural 
pre-seasonal immunity in the population (risk of infection in 
unvaccinated subjects), which may vary independently or 
in correlation. Thus, estimates of vaccine effectiveness that 
are based on non-specific endpoints show larger variation 
than estimates based on specific endpoints. This increase 
in variability is unavoidable.
If in influenza vaccine effectiveness studies non-
specific endpoints are employed not as a surrogate for 
influenza infection, but because the endpoint is serious or 
life-threatening, the question arises, how to interpret the 
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resulting effectiveness estimate. VEI is easy to interpret: an 
estimate of 0.35 means a moderate vaccine effectiveness 
against influenza infection (only 35% of influenza cases 
prevented), given the maximum possible value of 1.0 
(100% of influenza cases prevented.) For VEE such univocal 
interpretation in terms of low, moderate or high is less 
straightforward. The reason for this is that its maximum 
possible value is as we saw less than 1.0, and usually 
unknown. An estimate of 0.15 means 15% of endpoint 
cases prevented, but it is impossible to decide if this is a 
low or high effectiveness. To be able to use the adjectives 
low or high, the “costs” of an endpoint case have to be 
taken into account. For some endpoints, for example 
death from all causes, 5% of cases prevented [8] may be 
considered an excellent influenza vaccine effectiveness, 
while for other endpoints it may imply a low effectiveness.
Finally, as noted in the Introduction, it is often 
thought that when a non-specific endpoint is employed as 
surrogate for influenza infection VEI will be underestimated, 
that VEE < VEI. From our formula it follows that this need 
not be the case. Overestimation of VEI may occur when 
vaccinated infected influenza cases are less susceptible to 
the endpoint than unvaccinated infected cases. This was 
already known for specific endpoints, when  the specificity 
of the laboratory test is lower for vaccinated infected 
subjects than for unvaccinated infected subjects [3]. With 
our formula this can now be generalized to all endpoints, 
including non-specific ones.
In conclusion: variation in VEE is unavoidable as 
it is inherent to the measure, and its extent is such that 
the results of single studies using specific or non-specific 
endpoints may not be representative of the performance 
of influenza vaccines in general. Their use as basis for 
health care decisions and vaccination policies should be 
reconsidered. 
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The risks discussed here are probabilities, the probabilities than certain clinical events –influenza infection, an influenza-
related outcome– occur. We investigated the relationship between VEE and VEI by applying a basic probability rule to these 
risks. Before presenting our derivation, we first introduce two other risks/probabilities: 
R(E|I): Risk of the outcome given being influenza infected 
R(E|¬I): Risk of the outcome given not being influenza infected (with not denoted by the symbol ¬)
These risks are so-called conditional risks, with the condition given after the symbol |. For the first risk the condition is: 
being influenza infected, for the second risk the condition is: not being influenza infected. An outcome is influenza-related if 
R(E|I) >R(E|¬I). The basic probability rule we use is
R(E) = [R(E|I) – R(E|¬I)]·R(I) + R(E|¬I) 
Define
 
Rv(E|I) = γ·Ru(E|I)   
RRu(E) = Ru(E|I)/Ru(E|¬I)
VEI = 1–Rv(I)/Ru(I)
and assume that
  
Rv(E|¬I) = Ru(E|¬I) = R(E|¬I)
that is, assume that the risk of the outcome does not differ between vaccinated and unvaccinated non-infected subjects. 
Then, with the basic probability rule and some simple algebra it follows that
[Ru(E) – Rv(E)]
 = [Ru(E|I) – Ru(E|¬I)]·Ru(I) + Ru(E|¬I) – [Rv(E|I) – Rv(E|¬I)]·Rv(I) – Rv(E|¬I)
 = [Ru(E|I) – R(E|¬I)]·Ru(I) + R(E|¬I) – [γ·Ru(E|I) – R(E|¬I)]·Rv(I) – R(E|¬I)
 = [Ru(E|I) – R(E|¬I)]·Ru(I) – [γ·Ru(E|I) – R(E|¬I)]·Rv(I) 
 = [Ru(E|I) – R(E|¬I)]·Ru(I) – [γ·Ru(E|I) – R(E|¬I)]·(1–VEI)·Ru(I) 
 = [RRu(E)·Ru(E|¬I) –R(E|¬I)]·Ru(I) – [γ·RRu(E)·Ru(E|¬I) – R(E|¬I)]·(1–VEI)·Ru(I) 
 = [RRu(E)·R(E|¬I) –R(E|¬I)]·Ru(I) – [γ· RRu(E)·R(E|¬I) – R(E|¬I)]·(1 –VEI)·Ru(I) 
 = (RRu(E) –1)·R(E|¬I)·Ru(I) – [(γ·RRu(E) –1]·R(E|¬I)·(1–VEI)·Ru(I) 
Ru(E) = [Ru(E|I) –Ru(E|¬I)]·Ru(I) + Ru(E|¬I)
 = [Ru(E|I)/Ru(E|¬I) –1]·Ru(E|¬I)]·Ru(I) + Ru(E|¬I)
 = (RRu(E) –1)·R(E|¬I)·Ru(I) + R(E|¬I)
Hence
VEE = 1–Rv(E)/Ru(E) 
 = [Ru(E) –Rv(E)]/Ru(E)
      (RRu(E) –1) – (γ·RRu(E) –1)·(1–VEI) 
 =  ———————————————      
              (RRu(E) –1) + 1/Ru(I) 
When γ = 1, RRu(E) = RR(E) and the formula above simplifies to
              (RR(E) –1)·VEI
 VEE =  ————————        
          (RR(E) –1) + 1/Ru(I) 
APPENDIX – DERIVATION OF THE FORMULA
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